Teva returns unwanted stem cell heart drug to Mesoblast – FierceBiotech
FierceBiotech |
Teva returns unwanted stem cell heart drug to Mesoblast
FierceBiotech Credit Suisse believes that drug could be worth $4.1 billion in peak annual sales, but stem cell therapies have waxed and waned in both popularity and testing results over the years, with many in Big Pharma deciding to pull out of stem cell therapy pacts. Mesoblast regains full rights to stem cell heart failure treatment Mesoblast dives 42pc after partner Teva withdraws from heart failure trials |
